Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 177Lu-FAP-2286 |
| Synonyms | |
| Therapy Description |
177Lu-FAP-2286 is a radioconjugate comprising a FAP-binding cyclic peptide linked to a DOTA chelator labeled with the radionuclide Lutetium-177, which potentially inhibits growth of FAP-expressing tumors (PMID: 35608703). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 177Lu-FAP-2286 | 177-FAP-2286|FAP-2286|FAP 2286|Lutetium Lu 177-FAP-2286 | 177Lu-FAP-2286 is a radioconjugate comprising a FAP-binding cyclic peptide linked to a DOTA chelator labeled with the radionuclide Lutetium-177, which potentially inhibits growth of FAP-expressing tumors (PMID: 35608703). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04939610 | Phase Ib/II | 177Lu-FAP-2286 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) | Recruiting | USA | CAN | AUS | 0 |